High-throughput virtual screening, identification and in vitro biological evaluation of novel inhibitors of signal transducer and activator of transcription 3

Medicinal Chemistry Research

Volumn 24, Issue 6, 2015, Pages 2694-2708

  Singh, Pushpendra ^a   Bast, Felix ^a  

^a CENTRAL UNIVERSITY OF PUNJAB   (India)

Author keywords

Inter Bio Screen natural compound library (IBS); Maestro 9.6; Natural compounds; Signal transducer and activator of transcription

Indexed keywords

ANTINEOPLASTIC AGENT; EPIGALLOCATECHIN GALLATE; EPIGALLOCATECHOL; MESSENGER RNA; MORIN; MYRICETIN; PROTEIN INHIBITOR OF ACTIVATED STAT; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL COUNT; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; CRYSTAL STRUCTURE; CYTOTOXICITY; DIMERIZATION; DNA BINDING; DRUG BIOAVAILABILITY; DRUG IDENTIFICATION; DRUG SCREENING; GENE EXPRESSION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL CARCINOMA; LUNG CARCINOMA; MOLECULAR DOCKING; OXIDATIVE STRESS; PROSTATE CANCER; PROTEIN DNA INTERACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; X RAY;

EID: 84930927156     PISSN: 10542523     EISSN: 15548120     Source Type: Journal    
DOI: 10.1007/s00044-015-1328-6     Document Type: Article

References (64)

1. Aggarwal BB, Kunnumakkara AB, Harikumar KB, Gupta SR, Tharakan ST, Koca C, Dey S, Sung B (2009) Signal transducer and activator of transcription-3, inflammation, and cancer. Ann N Y Acad Sci 1171:59-76
2. Alimova IN, Liu B, Fan Z, Edgerton SM, Dillon T, Lind SE, Thor AD (2009) Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle 8:909-915
3. Azare J, Leslie K, Al-Ahmadie H, Gerald W, Weinreb PH, Violette SM, Bromberg J (2007) Constitutively activated Stat3 induces tumorigenesis and enhances cell motility of prostate epithelial cells through integrin β6. Mol Cell Biol 27:4444-4453
4. Becker S, Groner B, Müller CW (1998) Three-dimensional structure of the Stat3β homodimer bound to DNA. Nature 394:145-151
5. Bhanot A, Sharma R, Noolvi MN (2011) Natural sources as potential anti-cancer agents: a review. Int J Phytomed 3:09-26
6. Bill A, Schmitz A, König K, Heukamp LC, Hannam JS, Famulok M (2012) Anti-proliferative effect of cytohesin inhibition in Gefitinib-resistant lung cancer cells. PLoS ONE 7:e41179
7. Cho JY, Park J (2008) Contribution of natural inhibitors to the understanding of the PI3K/PDK1/PKB pathway in the insulin-mediated intracellular signaling cascade. Int J Mol Sci 9:2217-2230
8. Chung CD, Liao J, Liu B, Rao X, Jay P, Berta P, Shuai K (1997) Specific inhibition of Stat3 signal transduction by PIAS3. Science 278:1803-1805
9. Connors SK, Chornokur G, Kumar NB (2012) New insights into the mechanisms of green tea catechins in the chemoprevention of prostate cancer. Nutr Cancer 64:4-22
10. Cragg GM, Newman DJ (2005) Plants as a source of anti-cancer agents. J Ethnopharmacol 100:72-79
11. Da Rocha AB, Lopes RM, Schwartsmann G (2001) Natural products in anticancer therapy. Curr Opin Pharmacol 1:364-369
12. Dave B, Landis MD, Dobrolecki LE, Wu M-F, Zhang X, Westbrook TF, Hilsenbeck SG, Liu D, Lewis MT, Tweardy DJ (2012) Selective small molecule stat3 inhibitor reduces breast cancer tumor-initiating cells and improves recurrence free survival in a human-xenograft model. PLoS ONE 7:e30207
13. Debnath B, Xu S, Neamati N (2012) Small molecule inhibitors of signal transducer and activator of transcription 3 (Stat3) protein. J Med Chem 55:6645-6668
14. Fletcher S, Turkson J, Gunning PT (2008) Molecular approaches towards the inhibition of the signal transducer and activator of transcription 3 (Stat3) protein. ChemMedChem 3:1159-1168
15. Friedbichler K, Kerenyi MA, Müllner EW, Moriggl R (2009) Stat5 as hematopoietic gatekeeper and oncogene upon tyrosine kinase-induced transformation. JAK-STAT Pathw Dis 131
16. Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, Repasky MP, Knoll EH, Shelley M, Perry JK (2004) Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 47:1739-1749
17. Friesner RA, Murphy RB, Repasky MP, Frye LL, Greenwood JR, Halgren TA, Sanschagrin PC, Mainz DT (2006) Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J Med Chem 49:6177-6196
18. Gooch JL, Christy B, Yee D (2002) STAT6 mediates interleukin-4 growth inhibition in human breast cancer cells. Neoplasia 4:324
19. Grivennikov SI, Karin M (2010) Dangerous liaisons: STAT3 and NF-κB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev 21:11-19
20. Halgren TA, Murphy RB, Friesner RA, Beard HS, Frye LL, Friesner RA, Murphy RB, Repasky MP, Frye LL, Greenwood JR, Halgren TA, Sanschagrin PC, Mainz DT et al (2004) Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J Med Chem 47:1750-1759
21. Hillman GG (2012) Dietary agents in cancer chemoprevention and treatment. J Ooncology
22. Huang AJ, Moffat B, Yansura DG (2005a) Heteromultimeric molecules. Google Patents
23. Huang HF, Murphy TF, Shu P, Barton AB, Barton BE (2005b) Stable expression of constitutively-activated STAT3 in benign prostatic epithelial cells changes their phenotype to those resembling malignant cells. Mol Cancer 4
24. Huang W, He T, Chai C, Yang Y, Zheng Y, Zhou P, Qiao X, Zhang B, Liu Z, Wang J (2012) Triptolide inhibits the proliferation of prostate cancer cells and down-regulates SUMO-specific protease 1 expression. PLoS ONE 7:e37693
25. Jorgensen WL, Duffy EM (2002) Prediction of drug solubility from structure. Adv Drug Deliv Rev 54:355-366
26. Jorgensen WL, Tirado-Rives J (1988) The OPLS [optimized potentials for liquid simulations] potential functions for proteins, energy minimizations for crystals of cyclic peptides and crambin. J Am Chem Soc 110:1657-1666
27. Jorgensen WL, Maxwell DS, Tirado-Rives J (1996) Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids. J Am Chem Soc 118:11225-11236
28. Kumamoto T, Fujii M, Hou D-X (2009) Myricetin directly targets JAK1 to inhibit cell transformation. Cancer Lett 275:17-26
29. Lin H-Y, Hou S-C, Chen S-C, Kao M-C, Yu C-C, Funayama S, Ho C-T, Way T-D (2012) (-)-Epigallocatechin gallate induces Fas/CD95-mediated apoptosis through inhibiting constitutive and IL-6-induced JAK/STAT3 signaling in head and neck squamous cell carcinoma cells. J Agric Food Chem 60:2480-2489
30. Liu B, Ordonez-Ercan D, Fan Z, Edgerton SM, Yang X, Thor AD (2007) Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells. Int Cancer 120:1874-1882
31. Lu JJ, Crimin K, Goodwin JT, Crivori P, Orrenius C, Xing L, Tandler PJ, Vidmar TJ, Amore BM, Wilson AG (2004) Influence of molecular flexibility and polar surface area metrics on oral bioavailability in the rat. J Med Chem 47:6104-6107
32. Mereles D, Hunstein W (2011) Epigallocatechin-3-gallate (EGCG) for clinical trials: more pitfalls than promises? Int J Mol Sci 12:5592-5603
33. Nam S, Smith DM, Dou QP (2001) Ester bond-containing tea polyphenols potently inhibit proteasome activity in vitro and in vivo. J Biol Chem 276:13322-13330
34. Ni Z, Lou W, Leman ES, Gao AC (2000) Inhibition of constitutively activated Stat3 signaling pathway suppresses growth of prostate cancer cells. Cancer Res 60:1225-1228
35. Niu G, Heller R, Catlett-Falcone R, Coppola D, Jaroszeski M, Dalton W, Jove R, Yu H (1999) Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo. Cancer Res 59:5059-5063
36. Niu G, Shain KH, Huang M, Ravi R, Bedi A, Dalton WS, Jove R, Yu H (2001) Overexpression of a dominant-negative signal transducer and activator of transcription 3 variant in tumor cells leads to production of soluble factors that induce apoptosis and cell cycle arrest. Cancer Res 61:3276-3280
37. Phillips P, Sangwan V, Borja-Cacho D, Dudeja V, Vickers S, Saluja A (2011) Myricetin induces pancreatic cancer cell death via the induction of apoptosis and inhibition of the phosphatidylinositol 3-kinase (PI3K) signaling pathway. Cancer Lett 308:181-188
38. Phosrithong N, Ungwitayatorn J (2010) Molecular docking study on anticancer activity of plant-derived natural products. Med Chem Res 19:817-835
39. Rawlings JS, Rosler KM, Harrison DA (2004) The JAK/STAT signaling pathway. J Cell Sci 117:1281-1283
40. Roell D, Baniahmad A (2011) The natural compounds atraric acid and N-butylbenzene-sulfonamide as antagonists of the human androgen receptor and inhibitors of prostate cancer cell growth. Mol Cell Endocrinol 332:1-8
41. Sarkar FH, Li Y (2006) Using chemopreventive agents to enhance the efficacy of cancer therapy. Cancer Res 66:3347-3350
42. Schindler C, Levy DE, Decker T (2007) JAK-STAT signaling: from interferons to cytokines. J Biol Chem 282:20059-20063
43. Shen X, Zhang Y, Feng Y, Zhang L, Li J, Xie Y-A, Luo X (2014) Epigallocatechin-3-gallate inhibits cell growth, induces apoptosis and causes S phase arrest in hepatocellular carcinoma by suppressing the AKT pathway. Int J Oncol 44:791-796
44. Shim J-H, Su Z-Y, Chae J-I, Kim DJ, Zhu F, Ma W-Y, Bode AM, Yang CS, Dong Z (2010) Epigallocatechin gallate suppresses lung cancer cell growth through Ras-GTPase-activating protein SH3 domain-binding protein 1. Cancer Prev Res 3:670-679
45. Shivakumar D, Williams J, Wu Y, Damm W, Shelley J, Sherman W (2010) Prediction of absolute solvation free energies using molecular dynamics free energy perturbation and the OPLS force field. J Chem Theory Comput 6:1509-1519
46. Siddiqui IA, Adhami VM, Afaq F, Ahmad N, Mukhtar H (2004) Modulation of phosphatidylinositol-3-kinase/protein kinase B, and mitogen-activated protein kinase-pathways by tea polyphenols in human prostate cancer cells. J Cell Biochem 91:232-242
47. Simon AR, Rai U, Fanburg BL, Cochran BH (1998) Activation of the JAK-STAT pathway by reactive oxygen species. Am J Physiol Cell Physiol 275:C1640-C1652
48. Singh P, Bast F (2014a) In silico molecular docking study of natural compounds on wild and mutated epidermal growth factor receptor. Med Chem Res 23:5074-5085
49. Singh P, Bast F (2014b) Multitargeted molecular docking study of plant-derived natural products on phosphoinositide-3 kinase pathway components. Med Chem Res 23:1690-1700
50. Sunil H (2012) Inhibition studies of naturally occurring terpene based compounds with cyclin-dependent kinase 2 enzyme. J Comput Sci Syst Bio 5:2
51. Takeda K, Akira S (2000) STAT family of transcription factors in cytokine-mediated biological responses. Cytokine Growth Factor Rev 11:199-207
52. Takeda K, Noguchi K, Shi W, Tanaka T, Matsumoto M, Yoshida N, Kishimoto T, Akira S (1997) Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc Natl Acad Sci USA 94:3801
53. Turkson J, Zhang S, Palmer J, Kay H, Stanko J, Mora LB, Sebti S, Yu H, Jove R (2004) Inhibition of constitutive signal transducer and activator of transcription 3 activation by novel platinum complexes with potent antitumor activity. Mol Cancer Ther 3:1533-1542
54. Turkson J, Zhang S, Mora LB, Burns A, Sebti S, Jove R (2005) A novel platinum compound inhibits constitutive Stat3 signaling and induces cell cycle arrest and apoptosis of malignant cells. J Biol Chem 280:32979-32988
55. Walker EH, Pacold ME, Perisic O, Stephens L, Hawkins PT, Wymann MP, Williams RL (2000) Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol Cell 6(4):909-919
56. Wang Y, Ren X, Deng C, Yang L, Yan E, Guo T, Li Y, Xu MX (2013) Mechanism of the inhibition of the STAT3 signaling pathway by EGCG. Oncol Rep 30:2691-2696
57. Watowich SS, Hilton DJ, Lodish HF (1994) Activation and inhibition of erythropoietin receptor function: role of receptor dimerization. Mol Cell Bio 14:3535-3549
58. Yu H, Kortylewski M, Pardoll D (2007) Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 7:41-51
59. Yu H, Pardoll D, Jove R (2009) STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 9:798-809
60. Yue P, Turkson J (2009) Targeting STAT3 in cancer: how successful are we? Expert Opin Investig Drugs
61. Zgheib A, Lamy S, Annabi B (2013) Epigallocatechin gallate targeting of membrane type 1 matrix metalloproteinase-mediated Src and Janus kinase/signal transducers and activators of transcription 3 signaling inhibits transcription of colony-stimulating factors 2 and 3 in mesenchymal stromal cells. J Biol Chem 288:13378-13386
62. Zhang M, Zhu W, Ding N, Zhang W, Li Y (2013) Identification and characterization of small molecule inhibitors of signal transducer and activator of transcription 3 (STAT3) signaling pathway by virtual screening. Bioorg Med Chem Lett 23:2225-2229
63. Zhang S, Wang L, Liu H, Zhao G, Ming L (2014) Enhancement of recombinant myricetin on the radiosensitivity of lung cancer A549 and H1299 cells. Diagn Pathol 9:68
64. Zhu B-H, Chen H-Y, Zhan W-H, Wang C-Y, Cai S-R, Wang Z, Zhang C-H, He Y-L (2011) (-)-Epigallocatechin-3-gallate inhibits VEGF expression induced by IL-6 via Stat3 in gastric cancer. World J Gastroenterol 17:2315